APA (7th ed.) Citation

Buckley, H. L., Collinson, F. J., Ainsworth, G., Poad, H., Flanagan, L., Katona, E., . . . Vasudev, N. S. (2019). PRISM protocol: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. BMC Cancer, 19(1), 1. https://doi.org/10.1186/s12885-019-6273-1

Chicago Style (17th ed.) Citation

Buckley, Hannah L., et al. "PRISM Protocol: A Randomised Phase II Trial of Nivolumab in Combination with Alternatively Scheduled Ipilimumab in First-line Treatment of Patients with Advanced or Metastatic Renal Cell Carcinoma." BMC Cancer 19, no. 1 (2019): 1. https://doi.org/10.1186/s12885-019-6273-1.

MLA (9th ed.) Citation

Buckley, Hannah L., et al. "PRISM Protocol: A Randomised Phase II Trial of Nivolumab in Combination with Alternatively Scheduled Ipilimumab in First-line Treatment of Patients with Advanced or Metastatic Renal Cell Carcinoma." BMC Cancer, vol. 19, no. 1, 2019, p. 1, https://doi.org/10.1186/s12885-019-6273-1.